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ACK Ammonium-Chloride-Potassium lysis buffer 
Ad5 Serotype 5 adenoviruses 
Ad3 Serotype 3 adenoviruses 
APCs Antigen presenting cells 
BD Becton Dickinson 
CBA Cytometric bead array 
DCs Dendritic cells           
DMEM Dulbecco’s modified Eagle’s medium 
GMCSF Granulocyte macrophage colony stimulation factor 
hCD40L Human CD40 Ligand 
hTERT Human telomerase reverse transcriptase 
IFN-gamma Interferon gamma 
IL4 Interleukin 4 
IL6 Interleukin 6 
IL2 Interleukin 2 
IL10 Interleukin 10 
IL12 Interleukin 12 
LPS Lipopolysaccharide 
NK Natural killer cells  
rhCD40L recombinant human CD40 Ligand 
Th1 T helper type 1  cells 
Th2 T helper type 2  cells 
TGF-β Transforming growth factor - beta 
TME Tumor microenvironment 
VEGF Vascular endothelial growth factor 
Abstract 21 
Dendritic cells (DCs) are crucial players in promoting immune responses. Logically, adoptive DC 22 
therapy is a promising approach in cancer immunotherapy. One of the major obstacles in cancer 23 
immunotherapy in general is the immunosuppressive tumor microenvironment, which hampers the 24 
maturation and activation of DCs. Therefore, human clinical outcomes with DC therapy alone have 25 
been disappointing. In this study, we use fully serotype 3 oncolytic adenovirus Ad3-hTERT-CMV-26 
hCD40L, expressing human CD40L, to modulate the tumor microenvironment with subsequently 27 
improved function of DCs. We evaluated the synergistic effects of Ad3-hTERT-CMV-hCD40L and 28 
DCs in the presence of human peripheral blood mononuclear cells ex vivo and in vivo. Tumors treated 29 
with Ad3-hTERT-CMV-hCD40L and DCs featured greater antitumor effect compared with unarmed 30 
virus or either treatment alone. 100% of humanized mice survived to the end of the experiment, while 31 
mice in all other groups died by day 88. Moreover, adenovirally-delivered CD40L induced activation 32 
of DCs, leading to induction of Th1 immune responses. These results support clinical trials with Ad3-33 
hTERT-CMV-hCD40L in patients receiving DC therapy.  34 
 35 
Introduction 36 
The field of cancer immunotherapy has made tremendous progress recently and it has become a first 37 
or second line treatment option for many cancers. To establish a powerful anti-tumor immune 38 
response in patients, successful tumor antigen presentation through antigen-presenting cells (APCs), 39 
such as dendritic cells (DCs), to tumor-specific T cells is essential [1]. DCs are APCs and key 40 
mediators of adaptive immune responses [2]. Considering the key role of DCs in the initiation and 41 
regulation of immune responses, they are an attractive tool for immunotherapy [1]. DC-based 42 
therapies have been investigated for various advanced-stage cancers such as prostate cancer, 43 
melanoma, renal cell carcinoma, and B-cell lymphoma [3]. However, the typical tumor 44 
microenvironment (TME) is highly immunosuppressive and capable of impairing DC functions, 45 
thereby hampering the efficacy of DC therapies [4-6]. Thus, despite promising preclinical results in 46 
DC therapy, clinical data has suggested that alone it may not be sufficient to reverse the immune-47 
suppressive TME for meaningful responses in patients [7,8].  48 
For example, a randomized trial in colorectal cancer concluded that although anti-tumor immune 49 
responses could be induced with DC therapy, this did not result in anti-tumor efficacy or a survival 50 
advantage [9]. Similarly, in melanoma, a survival advantage was not seen versus chemotherapy [10]. 51 
Taken together with dozens of non-randomized trials, it appears that DC therapies are able to induce 52 
anti-tumor immunity but there is a limitation with efficacy, and tumor immunosuppression appears 53 
the likely culprit. This notion is supported by more promising trial results when DC therapy was given 54 
as an adjuvant therapy, in the context of minimal residual disease [11]. If there is no macroscopic 55 
tumor, there is less immunosuppression caused by the TME.  56 
Of note, it has repeatedly been suggested that patients responding immunologically to DC therapy 57 
have better outcomes [12-15]. This finding could indicate that immune competent patients have better 58 
outcomes than highly immune suppressed patients [16-18], without DCs necessarily playing a role. 59 
An interesting outlier to lack of randomized efficacy is sipuleucel T, which is a mixed product 60 
containing T cells and DCs. It can be speculated that the survival advantage attributed to this cell 61 
product might relate to the presence of T cells in the product [19].  62 
Thus, with tumor immunosuppression identified as the likely reason for lack of efficacy of DC 63 
therapy, one option would be to sensitize the tumor milieu to DCs [20]. Anti-tumor immune response 64 
depends on the amount and type of infiltrating immune cells, stromal cells, and MHC expression on 65 
tumor cells. During cancer progression, immunoediting and various escape tactics employed by 66 
tumors eventually prevent the host immune system from controlling tumors [21]. Thus, for a 67 
successful cancer immunotherapy, it is important to revert the immunosuppressiveness of the TME.  68 
Development of successful immune response requires multiple molecular signals. The primary signal 69 
is provided by binding of a tumor antigen to a T- or B-cell receptor, followed by secondary signals 70 
involving engagement of costimulatory proteins to their co-receptors on the surface of T or B 71 
lymphocytes. Additional signals, such as cytokine secretion, are necessary to further modify, enhance, 72 
and sustain the immune response against tumor cells. One of the key costimulatory molecules is the 73 
CD40 receptor [22] . CD40 is a member of the tumor necrosis factor receptor family and expressed 74 
by antigen-presenting cells such as DCs and B cells, whereas its ligand CD40L is transiently 75 
expressed on T cells. CD40 engagement on the surface of DCs induces expression of costimulatory 76 
molecules and cytokine production. Thus, the activation licenses DCs to mature and to trigger 77 
immune responses [22]. 78 
Oncolytic adenoviruses can be engineered to selectively replicate in and destroy tumor cells, 79 
providing an attractive platform for the treatment of cancer. In the larger context of cancer 80 
immunotherapy, oncolytic adenoviruses are especially promising for generating de novo immunity 81 
against tumors, and modifying the suppressive TME towards a proinflammatory status conducive to 82 
successful immunotherapy [23-26]. Thus, viruses appear attractive companion therapies for 83 
approaches such as DC therapy, T-cell therapies, and checkpoint inhibitors, all of which are hindered 84 
by the immunosuppressive TME.  85 
 86 
Arming the virus with immunostimulatory molecules such as CD40L enables efficient delivery of the 87 
therapeutic gene locally to the tumor, with local amplification and limited systemic exposure, which 88 
has proved to be an issue with recombinant CD40L. Then the recombinant molecule was given 89 
systemically, adverse events from non-target organs proved limiting to effective concentrations in 90 
tumors [27]. High local levels of CD40L cause apoptosis of CD40+ tumor cells [28], but since many 91 
advanced tumors are apoptosis-resistant, the DC-activating effect of CD40L could be more relevant 92 
in the context of cancer [28-30].  93 
Previously, oncolytic adenovirotherapy has demonstrated safety and efficacy in preclinical studies 94 
and in patients [25,31-35]. In one patient series, an oncolytic adenovirus coding for CD40L was used 95 
in advanced cancer patients refractory to available therapies [30], establishing safety of the approach. 96 
Possible signs of efficacy were reported in 83% of the treated patients. However, complete responses 97 
and long-term survival were rare, leaving room for improvement.  98 
We have shown that Ad3-hTERT-CMV-hCD40L, a CD40L-coding oncolytic adenovirus fully based 99 
on serotype 3 (Ad3), can elicit potent antitumor efficacy by coupling the lytic function with 100 
production of high amounts of CD40L at the tumor [36]. Importantly, the oncolytic platform restricts 101 
the expression of CD40L to cancer cells, reducing systemic exposure. Of note, Ad3 been shown to 102 
transduce tumors through the intravenous route both in patients and in animal models [25]. Previously 103 
published in vitro, in vivo, and human data has additionally revealed that virally expressed CD40L is 104 
able to stimulate DCs [24,30]. In this regard, we performed a pilot experiment where vectored 105 
delivery of mouse CD40L in a non-replicating virus was able to increase the efficacy of murine DC 106 
therapy [36]. Delivery of human CD40L in an oncolytic virus has not been previously studied in the 107 
context of human DC therapy.  108 
 109 
In the present study, we explored the potential benefit of oncolytic Ad3-hTERT-CMV-hCD40L in a 110 
clinically relevant “humanized” model of DC therapy featuring human peripheral blood mononuclear 111 
cells (PBMCs) as a source of immune cells. Synergistic effects of this approach were shown to lead 112 
to enhanced DC maturation and antitumor immune response. Our findings highlight the potential 113 
therapeutic benefit of Ad3-hTERT-CMV-hCD40L as an enabling therapy in patients receiving DC 114 
therapy. These preclinical results set the stage for clinical translation.  115 
 116 
Materials and Methods 117 
Cell lines 118 
Human A549 lung adenocarcinoma cell line, LNCaP prostate cancer cell line and SKOV3 ovarian 119 
cancer were obtained from American Type Culture Collection (ATCC; LGS standards, USA). EJ 120 
human bladder cancer cell line was a kindly provided by A.G.  Eliopoulos (University of Crete 121 
Medical School and Laboratory of Cancer Biology, Heraklion, Crete, Greece). All the cell lines 122 
except LNCaP were cultured in Dulbecco’s modified Eagles’s medium (DMEM) whereas LNCaP 123 
cells were cultured in Roswell Park Memorial Institute medium (RPMI). All the cell lines were 124 
maintained under a humidified 5% CO2 atmosphere at 37°C and media were supplemented with 1% 125 
Penicillin/Streptomycin (P/S), 1% L-Glutamine, 10% FBS. 126 
 127 
Viruses 128 
Two human oncolytic adenovirus based on serotype 3 were used:  Ad3-hTERT-E1A [34] and Ad3-129 
hTERT-CMV-hCD40L [36]. Both feature human telomerase reverse transcriptase promoter 130 
(hTERT), to restrict the virus replication in tumor cells.  131 
 132 
Generation of human DCs 133 
Generation of human DCs was done according to a protocol reported previously (Zafar et al., 2016). 134 
Briefly, human PBMCs were isolated from buffy coat of healthy donor obtained from Red Cross 135 
Blood Service (Helsinki, Finland). Isolation was done through density gradient centrifugation using 136 
lymphoprep (StemCell technologies). Isolated PBMCs were washed with PBS, and ACK lysis buffer 137 
(Sigma, St Louis, MO. A10492.01) was used to remove erythrocytes. CD14+ cells were isolated from 138 
PBMCs with CD14+ magnetic beads (Miltenyi Biotec, 130–050–201) according to the 139 
manufacturer’s instructions. 4.5 X106 CD14+ cells were cultured for 5-7 days in 10 ml of 10% RPMI 140 
supplemented with 1000U granulocyte-macrophage colony-stimulating factor (GMCSF, Peprotech) 141 
and 20ng interleukin 4 (IL4, Peprotech). Immature DCs were then incubated with 50 µg/ml tumor 142 
cell lysate for 24h, followed by incubation with lipopolysaccharide (LPS, 100ng) (Sigma, L4391-143 
1MG) for 17-24h. Maturation markers (CD80, CD86, CD83) of DCs were analyzed with flow 144 
cytometry. 145 
 146 
DC maturation and functionality assay  147 
Freshly isolated monocytes from PBMCs were cultured in a medium containing recombinant human 148 
GMCSF and IL4 to obtain immature DCs. The immature DCs were used in two maturation assays: 149 
first in the presence of Ad3-hTERT-E1A and Ad3-hTERT-CMV-hCD40L infected cells, and second 150 
in the presence of cell culture media supernatants collected from virus-infected cells. 151 
In the first assay, A549 cells were infected with Ad3-hTERT-E1A, Ad3-hTERT-CMV-hCD40L, or 152 
left uninfected. The cells were washed after 18h with PBS, and the infection media was replaced with 153 
fresh media containing monocyte-derived immature DCs. After 48h, maturation status of the DCs 154 
was assessed using flow cytometry. After this T cells isolated from fresh PBMCs through Pan T cell 155 
Isolation kit (Miltenyi Biotec, 130-096-535) were added to the mixture of DCs and virus-infected 156 
tumor cells. After 24h, T-cell activation was assessed with flow cytometry (see Supplementary Table 157 
1 for the list of antibodies).   158 
In the second assay, A549 cells were first infected with Ad3-hTERT-CMV-CD40L or Ad3-hTERT-159 
E1A and supernatants were collected and filtered to remove the viruses 48 hours later. The 160 
supernatants were added to fresh A549 cells together with monocyte-derived DCs. Similarly to the 161 
first assay, DC maturation was assayed after 48h, followed by an addition of T cells into the wells 162 
containing DCs and cancer cells. T-cell activation was measured through flow cytometry 24h later. 163 
LPS (100 ng) (Sigma, L4391–1MG) and recombinant hCD40L (500 ng) (Abcam, ab51956) were 164 
used as positive controls in both of the assays. The assay was done in triplicates. 165 
Cell viability assay 166 
10,000 A549, EJ, SKOV3 or LNCaP cells were plated in growth medium containing 2% FBS on 96-167 
well plates. After 24h, the cells were infected with Ad3-hTERT-CMV-hCD40L or Ad3-hTERT-E1A 168 
at concentrations of 1 viral particle (VP), 10 VP, 100 VP, or 1000 VP. Two days after the viral 169 
infection, DCs and human PBMCs were added in the wells. Tumor cells alone and DCs or PBMCs 170 
alone with virus were used as controls. Cell viability was normalized against the viability of controls. 171 
Cell viability was determined with MTS assay (CellTiter 96 AQueous One Solution, Promega, 172 
Madison, WI) starting from 24h to 96h after adding DCs and PBMCs. 173 
Animal experiment 174 
The experimental animal committee of the University of Helsinki and the Provincial Government of 175 
Southern Finland approved all animal protocols. Five weeks old immunodeficient SCID mice were 176 
implanted subcutaneously with 5 X 106 A549 cells. When the tumors become injectable 14 days after 177 
implantation [37], mice were divided into eight groups (n=10/group). Mice received intravenous 178 
injection of 10 X 106 HLA-matched PBMCs on day 0. Intratumoral injections of viruses (108 VP) 179 
were administered on days 1, 3, and 5, followed by 1 X 106 DCs on days 2, 4, and 6. Tumor growth 180 
was measured with electronic caliper every other day until day 44 and the survival was followed until 181 
day 112. Mice were euthanized when tumor size reached the limit of 18 mm, and tumor ulceration 182 
was considered as an exclusion criteria (excluded mice are shown in the figure with reversed 183 
triangles).  Tumors were collected, homogenized, filtered, and cultured overnight before analyzing 184 
with flow cytometry (See Supplementary Table 1 for the list of antibodies).  Part of the tumor samples 185 
were snap frozen and homogenized, to analyze various cytokines with CBA Flex set cytokine beads 186 
using BD Accuri C6. Results were analyzed with FCAP array software. 187 
 188 
 189 
 190 
 191 
Statistics: 192 
For statistical analyses, two tailed Student’s t-test, Two-way ANOVA (Tukey's multiple comparisons 193 
test), and log-rank were performed using Graphpad Prism (Graphpad Software Inc. La Jolla, CA). 194 
Statistical significance was considered when p<0.05. 195 
 196 
 197 
 198 
Results 199 
 200 
Tumor cells infected with Ad3-hTERT-CMV-hCD40L induce DC maturation, resulting in T-cell 201 
stimulation 202 
After incubating immature DCs with cancer cells infected with hCD40L-armed or parental unarmed 203 
virus, we observed statistically significant upregulation of DC maturation markers CD83, CD80, and 204 
CD86 compared with the non-infected mock group (p<0.0001; Figure 1A-C). Moreover, the DC 205 
maturation markers CD83 (p=0.0005) and CD80 (p=0.04) were significantly more upregulated if 206 
tumor cells were infected with Ad3-hTERT-CMV-hCD40L instead of the unarmed virus.  207 
To evaluate the functional consequences of DC stimulation, T cells were added to co-cultures 208 
resulting in high-level T-cell activation as measured by CD69 expression (Figure 1D and 1E). 209 
Intriguingly, the group containing Ad3-hTERT-CMV-hCD40L infected tumor cells showed 210 
significantly higher levels of T-cell activation compared with the group containing Ad3-hTERT-E1A 211 
infected tumor cells (p<0.05), indicating the importance of the arming device.    212 
Virally expressed hCD40L induces DC maturation and T-cell activation ex vivo 213 
To study the functionality of virally produced hCD40L, A549 cells were infected with hCD40L armed 214 
or unarmed virus and supernatants were collected and filtered for the assay. Immature DCs (CD14-, 215 
CD1a+) differentiated from CD14+ monocyte-enriched PBMCs were cultured with A549 tumor cells 216 
in the presence of filtered supernatants. After 48h, we evaluated co-cultured DCs for the expression 217 
of CD83, CD80, and CD86 (Figure 2A-C) with flow cytometry. We observed increased levels of 218 
maturation markers in groups incubated with filtered supernatants. Interestingly, co-culture of DCs 219 
in the presence of filtered supernatant containing hCD40L showed significant upregulation of DC 220 
maturation markers CD83 (p=0.0134)  and CD80 (p=0.0052) compared to DCs co-cultured in the 221 
presence of filtered supernatant collected from cells infected with unarmed virus, again suggesting 222 
relevance of hCD40L arming.  223 
We further assessed the activation capability of mature DCs to activate T cells in the presence of 224 
A549 tumor cells and filtered supernatants. Elevated levels of T-cell activation marker CD69 was 225 
observed on both CD3+CD4+ T cells and CD3+CD8+ T cells (2E and 2D). However, this increase 226 
in T cell activation between the positive control and treated groups has a trend towards significance. 227 
Especially CD3+CD4+ T cells showed significantly (p < 0.01)  higher activation in a group containing 228 
filtered supernatant collected from Ad3-hTERT-CMV-hCD40L infected cells, compared with Ad3-229 
hTERT-E1A infected supernatant.  230 
Ad3-hTERT-CMV-hCD40L improves DC- and PBMC-mediated cancer cell killing ex vivo 231 
The cytotoxic potency of Ad3-hTERT-CMV-hCD40L or Ad3-hTERT-E1A virus with DCs and 232 
PBMCs was assessed in two CD40 positive cell lines (LNCaP and  EJ) and two CD40 negative cell 233 
lines (SKOV3 and A549). Ad3-hTERT-CMV-hCD40L together with DCs and PBMCs induced 234 
complete cell killing at 1000 VP/cell in LNCaP (Figure 3A) and EJ cells (Figure 3B) 24h after adding 235 
DCs and PBMCs. In A549 cells (Figure 3D) and SKOV3 cells (Figure 3C) killing was observed 72h 236 
after adding DCs and PBMCs.  237 
The cytotoxic capacity of Ad3-hTERT-E1A, DCs, and PBMCs was less pronounced than the 238 
corresponding Ad3-hTERT-E1A-hCD40L triple therapy in all the cell lines except Skov3 (Figure 3 239 
E-H). Moreover, triple therapy with either armed or unarmed virus showed more prominent cell 240 
killing than double therapy (virus and DCs or virus and T cells) or virus alone groups. Thus, the 241 
CD40L-armed virus was able to enhance PBMCs-mediated cell killing even ex vivo when DCs were 242 
present. 243 
As expected, CD40L armed virus was more potent in CD40+ EJ and LNCaP cells compared with the 244 
unarmed virus. This was probably due to the proapoptotic effect of CD40L on CD40+ cancer cells 245 
[28]. There was no difference in the oncolytic potency of armed and unarmed virus alone in CD40- 246 
cells, suggesting that addition of transgene does not hamper the cell killing capacity of virus, which 247 
is in accordance with our previous findings (14).    248 
Ad3-hTERT-E1A-hCD40L and human DCs therapy results in antitumor effects and 100% survival 249 
of humanized mice  250 
To mimic the situation in humans, the ability of the virus to enhance DC therapy was studied in mice 251 
humanized by injection of human PBMCs intravenously [38,39]. Intratumoral injections of Ad3-252 
hTERT-CMV-hCD40L, Ad3-hTERT-E1A, or PBS, and maturated DCs was performed on alternate 253 
days. As, the goal of DC vaccines in the clinical use is to use ex vivo "trained" DCs, appropriately 254 
activated and loaded with tumor antigen, and thus capable of inducing strong antitumor T-cell 255 
responses, we chose to use mature DCs in the in vivo experiment to mimick the clinical setting. Tumor 256 
growth was followed until day 44 when the tumor growth in control groups reached the criteria 257 
determined by animal regulations. DCs or PBMCs alone were not able to inhibit tumor growth 258 
compared with the mock control group (Figure 4A). The group treated with the combination of 259 
PBMCs and DCs (Figure 4 and Supplementary Figure 1A) showed some tumor control but only the 260 
addition of oncolytic adenovirus (either hCD40L-armed or unarmed) inhibited tumor growth 261 
significantly (Figure 4 and Supplementary Figure 1A).  262 
The double therapy  or the triple therapy showed significant anti-tumor effect as compared with mock 263 
group (p<0.0001). However, tumor control was best in the group treated with hCD40L-armed virus, 264 
PBMCs, and DCs (Ad3-hTERT-E1A + PBMCs +DCs Vs Ad3-hTERT-CMV-hCd40L + PBMCs 265 
+DCs p< 0.001).  266 
Cancer specific survival data (Figure 4B and Supplementary Figure 1B) mirrored tumor control data. 267 
Mice treated with hCD40L-armed virus, PBMCs, and DCs showed a significant improvement in 268 
survival. Impressively, all mice remained alive until the end of the experiment. Thus, these results 269 
indicate that CD40L-armed virus is a potent enhancer of DC therapy when human T cells are present.   270 
 271 
DC therapy and Ad3-hTERT-CMV-hCD40L induce anti-tumor immune responses in the tumor 272 
microenvironment 273 
To investigate mechanism-of-action, four mice from each group were euthanized one week after the 274 
last administration of DCs. Analysis of the microenvironment revealed robust upregulation of DC 275 
maturation markers CD83, CD80, and CD86 in tumors treated with triple therapy (Figure 5A-C). 276 
Moreover, infiltration of significantly high levels of B and T lymphocytes in the same groups were 277 
also observed (Figure 5D and 5E). The immune modulation of the tumor microenvironment towards 278 
Th1 phenotype was further confirmed through the presences of high levels of  TNF alpha, IFN 279 
gamma, IL2, IL12, granzyme B and  IL6 in the same groups (Supplementary Figure 3). In summary, 280 
our findings suggest that expression of CD40L in the tumor induces maturation of DCs, leading to 281 
activation of adaptive immune response against the tumor. 282 
 283 
Discussion 284 
The highly immunosuppressive tumor microenvironment is a major obstacle to successful cancer 285 
immunotherapy in general and for DC therapy in particular [40-42]. Suppression results from  286 
complex interplay between soluble factors such as TGF-β, IL10, and VEGF [43-47], cell-bound 287 
molecules such as PD-L1, and cellular factors including regulatory T cells, myeloid-derived 288 
suppressor cells, and tumor-associated neutrophils [48].  Immunosuppression is associated with 289 
poor prognosis [16-18]. With regard to DC therapy, which is a promising approach with a solid 290 
theoretical basis, immunosuppressive factors hamper the ability of DCs to present antigens, 291 
thwarting the  stimulation of tumor-specific T cells [49]. Therefore, DC immunotherapy has not yet 292 
been successful enough to become a routine therapy in humans [42].  293 
 294 
CD40, as a target for cancer immunotherapy, has gained interest due to its capacity for activation 295 
of Th1 type immunity through DC maturation [28]. Interaction of CD40 with its natural ligand 296 
CD40L leads to activation of DCs, which is needed for T-cell activation [50]. Without this crucial 297 
signal for T-cell priming and proliferation, tumor-infiltrating T cells would undergo apoptosis 298 
[36,51,52]. Furthermore, CD40-CD40L interaction induces high levels of IL12 which in turn is 299 
responsible for the initiation of Th1 responses [53]. In addition, the interaction enhances DC 300 
capacity to promote IFN-gamma production by T cells [50,53].  301 
 302 
In preclinical studies, it has been reported that murine CD40L upregulates DC co-stimulatory 303 
receptors and induces antitumor immune responses [54,55].  In clinical use, CD40L has been used in 304 
different forms with encouraging results [27,30,56-58]. However, it has also been recognized that 305 
systemic administration is suboptimal as normal tissue damage seen, for example, as liver enzyme 306 
elevation, limits the concentration that can be achieved in tumors. Nevertheless, this creates the 307 
rationale for local production of CD40L, which has been explored in a few human pilot cohorts with 308 
promising results [30,59]. Although this approach seems to have anti-tumor activity, patients were 309 
not cured, providing the rationale for further improvements [30]. Of note, the oncolytic platform may 310 
provide many advantages over non-replicating vector approaches [28,30]. 311 
 312 
Oncolytic adenoviruses are an attractive platform for cancer immunotherapy due to their tumor-313 
specific replication, ability to infect different tumors, good stability in vivo, and favorable safety 314 
profile in humans [60,61]. In this study, we studied CD40L-armed adenovirus serotype 3 Ad3-315 
hTERT-CMV-hCD40L. It features the following important aspects: fully serotype 3 to enhance 316 
tumor transduction through the intravenous route, tumor selectivity due to the presence of hTERT 317 
promoter, and induction of apoptosis in CD40+ tumors [36]. As discussed before, the serotype 3 318 
platform may be advantageous to the ubiquitous Ad5 in several ways [25,36]. The primary receptor 319 
for Ad3, desmoglein-2, is highly expressed in advanced tumors [25,36], allowing enhanced tumor 320 
transduction. Moreover, it has been reported that fully Ad3 capsid allows effective intravenous 321 
delivery in animals and humans [25,36]. 322 
Virally expressed CD40L has previously shown to induce apoptosis of CD40+ tumors and also  323 
activates antigen-presenting cells [28,36,62]. We have shown previously that Ad3-hTERT-CMV-324 
hCD40L virus as well as virally coded hCD40L induces maturation of DCs ex vivo [36]. In the 325 
present study, we demonstrated the ability of Ad3-hTERT-CMV-hCD40L to facilitate DC therapy in 326 
a clinically relevant setting using human DCs, human PBMCs and human tumor cells or xenografts 327 
ex vivo and in vivo. The purpose of the ex vivo study was to evaluate the capability of virally produced 328 
CD40L to mediate tumor cell killing by enhancing the activation of DCs. Ad3-hTERT-CMV-329 
hCD40L demonstrated significantly higher DC activation seen as high expression of CD80, CD86, 330 
and CD83 in comparison to other groups. Furthermore, in co-cultures Ad3-hTERT-CMV-hCD40L 331 
and DCs activated CD4 + T cells and CD8+ T cells.  332 
CD40L stimulates and recruits DCs, leading to direct cytotoxic T-cell activation and skewing the 333 
immune response towards Th1 phenotype [28]. Accordingly, in our study stimulated DCs were able 334 
to activate T cells in co-cultures. Cell killing with armed or unarmed virus together with DCs and 335 
PBMCs was more prominent compared with single agent treatments. As expected, CD40+ tumor 336 
cells treated with Ad3-hTERT-CMV-hCD40L, DCs, and PBMCs  were more susceptible to the 337 
treatment compared to the CD40- tumor cells, although cell killing was achieved also in this group. 338 
This is in accordance with our previous findings, indicating that potential application of this virus is 339 
not restricted to CD40+ tumors [36]. 340 
Next, we tested the ability of Ad3-hTERT-CMV-hCD40L to sensitize the tumor microenvironment 341 
to DC therapy in vivo. The specificity of Ad3-hTERT-CMV-hCD40L virus and its human transgene 342 
hCD40L restricted the choice of animal model to immunodeficient SCID mice bearing human 343 
xenografts, as human CD40L would not activate mouse CD40 [28]. Key components of the human 344 
immune system were introduced by intravenous injections of human PBMCs (SCID mice lack murine 345 
B and T cells). We were also able to demonstrate the in vivo ability of Ad3-hTERT-CMV-hCD40L 346 
to polarize an immunosuppressive microenvironment towards a more immunogenic phenotype as  347 
upregulation of Th1 immune-stimulatory cytokines was observed. Even the unarmed Ad3-hTERT-348 
E1A virus alone was able to stimulate DCs as seen by high expression of CD80, CD86, and CD83 349 
and to activate T- cell and B-cell responses. The engagement of CD40 expressed on B cells and CD40L 350 
is also important for the initiation of humoral immune response. Moreover, it has been shown that 351 
this interaction leads to germinal center formation, antibody isotype switching and affinity 352 
maturation [63]. Thus, CD40 pathway is essential  for the survival of many cell types and is crucial in 353 
the generation of humoral immune response [22,64]. These responses, however, were more 354 
pronounced with Ad3-hTERT-CMV-hCD40L administered with DCs leading to the best tumor 355 
control and prolonged survival. We think that it is a promising starting point for human translation 356 
that death due to cancer could be prevented in 100% of mice in the key experimental group. 357 
In summary, we provide preclinical proof of principle for using Ad3-hTERT-CMV-hCD40L in 358 
cancer patients receiving DC therapy. Thus, Ad3-hTERT-CMV-hCD40L is a promising candidate 359 
for human clinical trials. 360 
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Figure Legends 376 
 377 
Figure 1: Ad3-hTERT-CMV-hCD40L infected tumor cells induce DC maturation and T-cell 378 
stimulation. A549 cells were infected with Ad3-hTERT-CMV-hCD40L, Ad3-hTERT-E1A, or left 379 
untreated. After 18 h, infection media were removed and cells were washed with PBS before adding 380 
monocyte-derived DCs added to co-cultures. LPS (100 ng) and recombinant hCD40L protein (500 ng) 381 
were used as positive controls. After 48 h, a portion of DCs was assayed for maturation by flow 382 
cytometry. Median fluorescence intensity (MFI) for CD83 (A), CD80 (B) and CD86 (C)  of CD11c+ 383 
populations. T cells were added to the wells and the activation status of CD4+ T cells (D) or CD8+ T 384 
cells (E) was determined after 24 h by the expression of CD69. The assay was done in triplicates. 385 
MFI: Median fluorescence intensity, LPS: lipopolysaccharide, rhCD40L: recombinant human 386 
CD40L, Ad3-hCD40L and Ad3: cells infected with Ad3-hTERT-CMV-hCD40L and Ad3-hTERT-387 
E1A viruses, respectively. Data presented as mean ±SEM *, P < 0.05. **, P < 0.01. ***, P < 0.001. 388 
****, P < 0.0001 by two tailed Student’s t-test . 389 
 390 
Figure 2: Virally expressed hCD40L induces DC maturation and T-cell activation ex vivo. A549 cells 391 
were infected with Ad3-hTERT-CMV-hCD40L or Ad3-hTERT-E1A and supernatants were 392 
collected and filtered. Immature DCs were cultured with filtered supernatants for 48hrs. LPS and 393 
recombinant hCD40L protein were used as positive controls. After 48h, a portion of DCs was 394 
evaluated for Median fluorescence intensity (MFI) for CD83 (A), CD80 (B) and CD86 (C)  of 395 
CD11c+ populations or co-cultured with T cells. Activation status of CD4 +T cells (D) and CD8+ T 396 
(E) cells was assessed 24h later by the expression of CD69. Cells were stained and analyzed by flow 397 
cytometry. The assay was done in triplicates. Data presented as mean ±SEM. *, P < 0.05 **; P < 398 
0.01. ***; P < 0.001****; P < 0.0001 by two tailed Student’s t-test. 399 
 400 
 401 
Figure 3: Ad3-hTERT-CMV-hCD40L virus, DCs and PBMCs efficiently kill tumor cells ex vivo. 402 
Tumor-killing potency of Ad3-hTERT-CMVhCD40L, DCs and PBMCs was assessed after 1 day (in 403 
LNCaP and EJ cells) and 3 days (in SKOV3, and A549 cells), after adding DCs and PBMCs in co-404 
culture. The assay was done in triplicates. Oncolytic potency of Ad3-hTER-E1A with DCs and 405 
PBMCs was evaluated after 3 days (in LNCaP cells), 2 days (in EJ cells) and 4 days (in SKOV3, and 406 
A549 cells), after adding DCs and PBMCs in co-culture. Data presented as mean ±SEM. Cell 407 
viability was normalized against the viability of controls (not shown). 408 
 409 
  410 
Figure 4: Ad3-hTERT-E1A-hCD40L, human PBMCs, and human DCs therapy enhanced antitumor 411 
effects and survival in mice. Antitumor efficacy (A) and cancer specific  survival (B) of humanized 412 
mice receiving DC therapy and injections of Ad3-hTERT-CMV-hCD40L or the unarmed control 413 
virus Ad3-hTERT-E1A. A549 tumors were implanted subcutaneously in immunodeficient SCID 414 
mice lacking B and T-cells. To humanize the white blood cell compartment of the mice, 10 X 106 415 
PBMCs were injected intravenously on day 0 (dashed arrow). Viruses (gray arrows) were injected at 416 
1 X 108 VP and DCs (black arrows), 1X106, were injected intratumorally three times alternatively. 417 
Tumor growth was monitored every other day. Ad3-hTERT-CMV-hCD40L and DCs therapy 418 
significantly reduced tumor growth as compared with other groups. Tumor growth is expressed as 419 
normalized tumor volume based on the values from the first day of virus injection. Data is presented 420 
as mean + SEM. ***, P < 0.001; ****, P < 0.0001. 1A by Two-way ANOVA (Tukey’s post-hoc test) 421 
and 1B  Kaplan-Meier survival was analyzed bylog-rank test. 422 
 423 
 424 
Figure 5: Immune response in the tumor microenvironment. Median fluorescence intensity (MFI) 425 
for CD83 (A), CD80 (B) and CD86 (C)  of CD11c+ populations. Percentage of the CD19+ B cell 426 
population (D) and CD8+CD69+ lymphocytes of the CD19-CD3+ parent population (E). Data is 427 
presented as mean + SEM. *, P < 0.05 **, P < 0.01. ***, P < 0.001, ****, P < 0.0001 428 
 429 
Supplementary Figure 1: Antitumor efficacy (A) and cancer specific  survival (B) of mice treated 430 
with PBMCs, DC therapy and injections of Ad3-hTERT-CMV-hCD40L or the unarmed control virus 431 
Ad3-hTERT-E1A. A549 tumors were implanted subcutaneously in immunodeficient SCID mice. To 432 
humanize the white blood cell compartment of the mice, 10 X 106 PBMCs were injected 433 
intravenously on day 0. Viruses were injected at 1 X 108 VP and 1X106 DCs, were injected 434 
intratumorally three times alternatively as indicated by arrows. Tumor growth is expressed as 435 
normalized tumor volume based on the values from the first day of virus injection. Data is presented 436 
as mean + SEM. Statistical significance is indicated by stars: *, P < 0.05 **, P < 0.01. ***, P < 0.001, 437 
****, P < 0.0001 1A by Two-way ANOVA (Tukey’s post-hoc test)  and 1B Kaplan-Meier survival 438 
was analyzed by log-rank test. Data shown here is the same as in Figure 4, but with main groups only.  439 
 440 
Supplementary Figure 2: Immune cell subset in the tumor microenvironment. Percentage of the 441 
CD8+CD25+ (A) and CD4+CD25+ (B) lymphocytes of the CD3+ parent population. Tumor 442 
samples were run in triplicate except Ad3-E1A +PBMCs +DCs group in which just one sample left 443 
for analysis . Data is presented as mean + SEM. *, P < 0.05  by student’s t test. 444 
Supplementary Figure 3: Intratumoral cytokines expression level: Cytokines from A549 tumors 445 
samples treated with dendritic cells (DCs) alone, PBMCs alone, Ad3-hTERT-E1A plus DCs and 446 
PBMCs (PBMCs + DCs + Ad3-E1A) and  Ad3-hTERT-CMV-hCD40L along with DCs  and PBMCs 447 
(PBMCs + DCs + Ad3-hCD40L) were measured with CBA Flex set. Error bars, + SEM. 448 
 449 
 450 
 451 
Supplementary Table 1: Antibodies used in the experiments 452 
 453 
Antibody Catalogue 
number 
Company 
Anti-Human CD3 FITC 11-0036-42 e-bioscience 
 
Anti-human CD4 PerCP/Cy5.5    317428 
 
Biolegend 
 
Anti-Human CD8a PE 
 
12-0089-42 
 
ebiosciences 
 
Anti-human CD69 APC 
 
310910 
 
Biolegend 
 
Anti-human CD25 APC 
 
302610 
 
Biolegend 
Mouse Anti-Human CD19                          
PE-Cy™7 
560728 BD 
 
Anti-human CD11c  
PerCP/Cy5.5 
 
301624 
 
Biolegend 
 
 
Anti-human CD80 FITC 
 
305205 
 
Biolegend 
 
Anti-human CD86 PE 
 
 305405 Biolegend 
 
Anti-Human CD83 APC  
 
17-0839-42 
 
e-bioscience 
 
 454 
 455 
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